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ABSTRACT
Background. The magnitude of the postoperative sys-
temic inflammatory response (SIR), as evidenced by
C-reactive protein (CRP), is associated with both short- and
long-term outcomes following surgery for colorectal can-
cer. The present study examined the impact of preoperative
dexamethasone on the postoperative SIR and complica-
tions following elective surgery for colorectal cancer.
Methods. Patients who underwent elective surgery, with
curative intent, for colorectal cancer at a single center
between 2008 and 2016 were included (n = 556) in this
study. Data on the use of preoperative dexamethasone were
obtained from anesthetic records, and its impact on CRP on
postoperative days (PODs) 3 and 4, as well as postopera-
tive complications, was assessed using propensity score
matching (n = 276).
Results. In the propensity score-matched cohort, preop-
erative dexamethasone was associated with fewer patients
exceeding the established CRP threshold of 150 mg/L on
POD 3 (odds ratio [OR] 0.42, 95% confidence interval [CI]
0.26–0.70, p\ 0.001) and fewer postoperative complica-
tions (OR 0.53, 95% CI 0.33–0.86, p = 0.009). Similar
results for both POD 3 CRP and complications were
observed when using propensity score-adjusted regression
(OR 0.40, 95% CI 0.28–0.57 and OR 0.57, 95% CI
0.41–0.80, respectively) and propensity score stratification
(OR 0.41, 95% CI 0.25–0.57 and OR 0.53, 95% CI
0.33–0.86, respectively).
Conclusions. Preoperative dexamethasone was associated
with a lower postoperative SIR and fewer complications
following elective surgery for colorectal cancer.
Colorectal cancer is a leading cause of mortality in the
developed world.1 Surgical resection continues to form the
cornerstone of its management but is itself associated with
significant morbidity and mortality.2 Long-term outcome is
primarily related to disease stage at presentation, however
it is increasingly understood that postoperative complica-
tions have a negative impact on oncologic outcome.3,4 In
addition, postoperative complications are associated with a
significant healthcare and societal cost.
Interleukin (IL)-6 and the more routinely available
C-reactive protein (CRP), measured in the postoperative
period, have been reported to be reliable markers of the
magnitude of the surgical trauma.5 Furthermore, an asso-
ciation between the magnitude of this postoperative
systemic inflammatory response (SIR) and the develop-
ment of postoperative infective complications has been
reported following surgery for colorectal cancer6–8 inde-
pendent of presentation,9 and surgical approach.10 In
addition, postoperative CRP and the threshold concentra-
tions established to predict the development of infective
complications have been reported to be associated with
complication severity.11,12 More recently, a comprehensive
systematic review suggested that CRP concentrations
[150 mg/L on postoperative days (PODs) 3–5 should
prompt investigation of potential postoperative complica-
tions such as anastomotic leak.13
There is good evidence that, compared with open sur-
gery, laparoscopic surgery is associated with a reduction in
the postoperative SIR.5 However, no definite causal rela-
tionship has yet been defined between attenuation of the
postoperative SIR and postoperative complications. Fur-
thermore, it remains to be seen whether strategies that
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attenuate the postoperative SIR may also reduce postop-
erative complication rates.
Corticosteroids, administered at the induction of
anesthesia, are associated with the prevention of post-
operative nausea and vomiting.14 Indeed, preoperative
dexamethasone has now been integrated into many ‘en-
hanced recovery’ and ‘fast track’ perioperative care
protocols, although the underlying mechanism remains
unclear.15 Furthermore, there is evidence that preopera-
tive administration of corticosteroids is associated with a
reduction in the postoperative SIR following abdominal
surgery.16,17
The aim of the present study was to examine the impact
of preoperative dexamethasone on the magnitude of the
postoperative SIR and complications following surgery for
colorectal cancer. A propensity score analysis was per-
formed due to significant imbalances in patient and
operative variables potentially associated with both the
postoperative SIR and complications.
PATIENTS AND METHODS
Patients
This retrospective observational study of a prospectively
collected database included patients who underwent
resection with curative intent for histologically confirmed
colorectal cancer in a single center between 2008 and 2016.
Patients without available anesthetic records, receiving
long-term corticosteroids, and who had existing inflam-
matory conditions, emergency surgery, or metastatic
disease were not included in the analysis.
Clinical, radiological, and pathological data of all
patients were reviewed by a specialist colorectal oncology
multidisciplinary team before and after surgery. All
patients received prophylactic antibiotics and venous
thromboprophylaxis prior to the induction of anesthesia as
per hospital policy. Furthermore, all patients were cared for
in line with a unit standardized perioperative care policy
that included early postoperative mobilization, early ent-
eral nutrition, and the avoidance of routine nasogastric or
peritoneal drainage. The use of epidural anesthesia was at
the discretion of the anesthetic and surgical teams. Patients
were administered dexamethasone intravenously prior to
the induction of anesthesia, and at the discretion of the
anesthetist, to reduce the likelihood of postoperative nausea
and vomiting.
On each POD patients were clinically assessed and had
blood samples, including serum CRP, obtained as standard
until discharged. Further postoperative investigation and
intervention was at the discretion of the patient’s surgical
team who were not blind to serum CRP results.
Methods
Clinicopathological data were collected prospectively in
a database, anonymized, and subsequently analyzed.
Recorded information included patient demographics, tumor
site, TNM stage (TNM, 5th edition, American Joint Com-
mitteee on Cancer), surgical approach, complications, and
preoperative and postoperative serum CRP measurements.
Serum concentrations of CRP (mg/L) were measured
using an autoanalyzer (Architect; Abbot Diagnostics,
Maidenhead, UK) with a lower detectable limit of 0.2 mg/L,
as was serum albumin (normal range 35–50 g/L). Exceeding
the established CRP threshold of 150 mg/L on PODs 3 or 4
was recorded.13 The preoperative modified Glasgow Prog-
nostic Score (mGPS) was calculated in patients for whom
preoperative serum CRP and albumin were available.18
Data regarding the use of dexamethasone for the pre-
vention of postoperative nausea and vomiting at the
induction of anesthesia, the use of epidural anesthesia, and
the need for intraoperative blood transfusion were collected
by retrospective review of anesthetic notes.
Complications were recorded and categorized by
severity using the Clavien–Dindo scale.19 Infective com-
plications were categorized as described elsewhere and
briefly summarized here.6 Wound (superficial surgical site)
infection was defined as the presence of pus either spon-
taneously discharging from the wound or requiring
drainage; deep surgical site infection was defined as sur-
gical or image-guided drainage of intra-abdominal pus;
anastomotic leak was defined as radiologically verified
fistula to bowel anastomosis or diagnosed at laparotomy;
pneumonia was defined by fever above 38.5 C and con-
solidatory chest X-ray findings requiring antibiotic
treatment; and septicemia was defined by the presence of
sepsis combined with positive blood culture. Urinary tract
infection was only included if complicated by septicemia
and confirmed with positive urine culture.
This study was approved by the West of Scotland
Research Ethics Committee, Glasgow, as part of a surgical
audit.
Statistical Analysis
In the initial unmatched cohort, categorical data were
compared using the v2 test. Data regarding postoperative
CRP were non-normal and are presented as medians and
ranges, and the medians of the two groups were compared
using the Mann–Whitney U test. The treatment effect of
preoperative dexamethasone in terms of exceeding the
postoperative CRP threshold and complications was dis-
played as odds ratios (ORs) and 95% confidence intervals
(CIs), while the magnitude of CRP by each POD was
displayed graphically as 95% CIs of the median.
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Multivariate logistic regression was used to generate a
propensity score for each patient, predicting the probability
of having received preoperative dexamethasone or not,
based on the following variables thought to be associated
with the postoperative SIR or complications: age, sex, body
mass index (BMI), smoking status, American Society of
Anesthesiologists (ASA) score, mGPS, tumor site, TNM
stage, neoadjuvant chemoradiotherapy, surgical approach
(open or laparoscopic), operation duration, blood transfu-
sion, stoma formation, and the use of epidural anesthesia.
Patients who received preoperative dexamethasone were
then matched 1:1 with a patient who did not, using the closest
propensity score on the logit scale (calliper\ 0.05, order of
match selection randomized, without replacement). Cate-
gorical data were compared using McNemar’s test, and
continuous data were compared using the related samples
Wilcoxon sign-rank test. The appropriateness of the
propensity score matching was assessed visually by fre-
quency of propensity scores in each group before and after
matching. In addition, the propensity scores were included as
a linear covariate alongside preoperative dexamethasone in
multivariate binary logistic regression models for exceeding
the POD 3 CRP threshold and postoperative complications.
Finally, the propensity scores were used to stratify the
patients by quintiles, from which an average treatment effect
was calculated for both the POD 3 CRP threshold and
postoperative complications as an OR and 95% CI.
In all tests, a two-sided p value\0.05 was considered
statistically significant. Propensity scoring and matching,
as well as all statistical analyses, were performed using
IBM SPSS version 21 for Windows (IBM Corporation,
Armonk, NY, USA).
RESULTS
Patient Characteristics
Overall, 556 patients were included in the study
(Table 1), of whom 310 were male (56%) and 360 (65%)
were over 65 years of age. Most had colonic (355, 64%)
and node-negative disease (375, 67%). Laparoscopic
resection was performed in 212 patients (38%), with the
remainder having open surgery. A postoperative compli-
cation occurred in 234 cases (42%), of which 151 (27%)
were infective and 47 (8%) were classified as Clavien–
Dindo grade 3–5 severity. Anastomotic leak occurred in 19
cases (3%), and there were 5 (1%) postoperative deaths.
Impact of Dexamethasone on All Patients
In the unmatched cohort, exceeding the CRP threshold
of 150 mg/L on POD 3 was significantly associated with
TABLE 1 Association between clinicopathological characteristics,
perioperative factors, and preoperative dexamethasone in patients
undergoing any surgery for colorectal cancer [n = 556]
Characteristic All [n (%)] Preoperative dexamethasone p value
No
n (%)
Yes
n (%)
n 556 (100) 245 (44) 311 (56) –
Age, years
\65 196 (35) 85 (35) 111 (36) 0.214
65–74 219 (40) 88 (36) 131 (42)
[74 141 (25) 72 (29) 69 (22)
Sex
Male 310 (56) 139 (57) 171 (55) 0.731
Female 246 (44) 106 (43) 140 (45)
BMI, kg/m2
\20 38 (7) 14 (6) 24 (8) 0.242
20–25 170 (32) 74 (32) 96 (31)
26–30 172 (32) 65 (28) 107 (35)
[30 156 (29) 76 (33) 80 (26)
Smoking
Never 251 (46) 114 (47) 137 (45) 0.706
Ex-smoker 223 (41) 94 (39) 129 (42)
Current 73 (13) 34 (14) 39 (13)
ASA score
1 136 (25) 50 (20) 86 (28) 0.003
2 248 (45) 108 (44) 140 (45)
3 155 (27) 74 (30) 81 (26)
4 16 (3) 13 (5) 3 (1)
Preop mGPS
0 429 (83) 179 (78) 250 (86) 0.007
1 40 (8) 21 (9) 19 (7)
2 48 (9) 29 (13) 19 (7)
Tumor site
Colon 355 (64) 159 (65) 196 (63) 0.658
Rectum 201 (36) 86 (35) 115 (37)
TNM stage
0 13 (2) 5 (2) 8 (3) 0.261
I 127 (23) 47 (19) 80 (27)
II 229 (42) 112 (46) 117 (38)
III 181 (33) 80 (33) 311 (32)
Neoadjuvant treatment
Yes 82 (15) 34 (15) 48 (16) 0.630
No 466 (85) 209 (85) 257 (84)
Approach
Open 337 (61) 195 (80) 142 (47) \0.001
Laparoscopic 212 (39) 49 (20) 163 (53)
Surgery[ 4 h
Yes 183 (33) 57 (23) 126 (41) \0.001
No 370 (67) 187 (77) 183 (59)
Intraoperative transfusion
Yes 29 (5) 21 (9) 8 (3) 0.002
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higher rates of any complication (60 vs. 29%, OR 3.60,
p\ 0.001), infective complications (42 vs. 16%, OR 3.87,
p\ 0.001), anastomotic leak (6 vs. 1%, OR 4.16,
p = 0.011), and Clavien–Dindo grade 3 or higher com-
plications (13 vs. 5%, OR 3.10, p = 0.001). In the
unmatched cohort (Table 1), 311 patients (56%) received
dexamethasone at the induction of anesthesia, of whom 194
received 4 mg and 117 received 8 mg, while 245 (44%) did
not. There were significant differences between those
patients who received preoperative dexamethasone and
those who did not, in ASA grade (p = 0.003), preoperative
mGPS (p = 0.007), laparoscopic surgery (52 vs. 20%,
p\ 0.001), surgery lasting more than 4 h (41 vs. 23%,
p\ 0.001), blood transfusion (3 vs. 9%, p = 0.002), and
epidural anesthesia (28 vs. 64%, p\ 0.001). A signifi-
cantly lower proportion of those who received preoperative
dexamethasone exceeded the established CRP threshold of
150 mg/L on POD 3 (33 vs. 55%, p\ 0.001), but not on
day 4. Preoperative dexamethasone was significantly
associated with fewer postoperative complications (36 vs.
50%, OR 0.40, p = 0.001) and infective complications (23
vs. 32%, OR 0.57, p = 0.021), but not anastomotic leak or
complication severity.
Impact of Dexamethasone on the Propensity Score-
Matched Cohort
Propensity scores could not be assigned to 156 patients
due to missing covariate data, leaving 400 patients with
propensity scores, of whom 262 had received dexametha-
sone at the induction of anesthesia and 138 had not
(Fig. 1). Overall, 276 patients (138 from each group) were
matched based on their propensity score, with a subsequent
improvement in the balance of the distribution of propen-
sity scores in each group (Fig. 2).
In the propensity score-matched cohort, exceeding the
CRP threshold of 150 mg/L on POD 3 was significantly
associated with higher rates of any complication (59 vs.
28%, OR 3.58, p\ 0.001), infective complications (44 vs.
15%, OR 4.38, p\ 0.001), and Clavien–Dindo grade 3 or
TABLE 1 continued
Characteristic All [n (%)] Preoperative dexamethasone p value
No
n (%)
Yes
n (%)
No 517 (95) 221 (91) 296 (97)
Stoma
Yes 164 (30) 72 (29) 92 (30) 0.926
No 390 (70) 173 (71) 217 (70)
Epidural
Yes 244 (44) 158 (64) 86 (28) \0.001
No 308 (56) 87 (36) 221 (72)
POD 3 CRP
mg/L
[median
(range)]
138 (9601) 166 (22–601) 118 (9–430) \0.001
POD 3 CRP[ 150 mg/L
Yes 239 (45) 136 (57) 103 (35) \0.001
No 292 (55) 101 (43) 191 (65)
POD 4 CRP,
mg/L
[median
(range)]
112 (13–528) 118 (13–528) 105 (15–415) 0.018
POD 4 CRP[ 150 mg/L
Yes 153 (33) 79 (36) 74 (31) 0.277
No 308 (67) 142 (64) 166 (69)
POD 3 albumin
Median
range, g/L
26 (7–40) 25 (14–35) 27 (7–40) \0.001
POD 3 albumin\ 25 g/L
Yes 189 (36) 104 (44) 85 (19) 0.001
No 332 (64) 130 (56) 202 (81)
POD 4 albumin
Median
range, g/L
26 (13–35) 25 (14–35) 27 (13–35) \0.001
POD 4 albumin\ 25 g/L
Yes 170 (37) 97 (44) 73 (31) 0.003
No 285 (63) 121 (56) 164 (69)
Any complication
Yes 234 (42)/321 122 (50) 112 (36) 0.001
No 321 (58) 123 (50) 198 (64)
Infective complications
Yes 151 (27) 79 (32) 72 (23) 0.021
No 440 (73) 166 (68) 238 (77)
Anastomotic leak
Yes 19 (3) 12 (5) 7 (2) 0.103
No 536 (97) 233 (95) 330 (98)
Clavien–Dindo grade
0–2 508 (92) 222 (91) 286 (92) 0.540
3–5 47 (8) 23 (9) 24 (8)
30 day mortality
Yes 5 (1) 3 (1) 2 (1) 0.659
No 550 (99) 242 (99) 308 (99)
TABLE 1 continued
Characteristic All [n (%)] Preoperative dexamethasone p value
No
n (%)
Yes
n (%)
Adjuvant treatment
Yes 152 (32) 61 (27) 91 (36) 0.031
No 325 (68) 165 (73) 160 (64)
BMI body mass index, ASA American Society of Anesthesiologists,
POD postoperative day, CRP C-reactive protein, mGPS preoperative
modified Glasgow Prognostic score, Preop preoperative
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higher complications (13 vs. 6%, OR 2.56, p = 0.032), but
not anastomotic leak (7 vs. 2%, OR 3.29, p = 0.068).
Following propensity score matching, the distribution of
patient and operative variables was balanced between the
two groups (Table 2). A significantly lower proportion of
those who received preoperative dexamethasone exceeded
the established CRP threshold of 150 mg/L on POD 3 (36
vs. 56%, OR 0.42, p = 0.001), but not on day 4. Preop-
erative dexamethasone was significantly associated with
fewer postoperative complications (34 vs. 49%, OR 0.53,
p = 0.001).
Other Propensity Score Analyses
Analysis of the impact of preoperative dexamethasone
on exceeding the POD 3 CRP threshold (Table 3) found a
similarly statistically significant probability reduction
using regression adjustment (OR 0.53, 95% CI 0.34–0.83),
propensity score stratification (OR 0.41, 95% 0.25–0.57),
and propensity score matching (0.42, 95% CI 0.26–0.70).
The same analysis of the impact of preoperative dexam-
ethasone on postoperative complications (Table 3) found a
similarly statistically significant probability reduction
using regression adjustment (OR 0.62, 95% CI 0.40–0.96),
propensity score stratification (OR 0.62, 95% 0.29–0.95),
and propensity score matching (0.53, 95% CI 0.33–0.86).
Time-Dependent Effect of Preoperative Dexamethasone
Dexamethasone at the induction of anesthesia had a
similar time-dependent effect on postoperative CRP in both
the unmatched and matched cohorts. There was a signifi-
cant reduction in CRP on PODs 1–3, with similar
concentrations from POD 4 onward.
DISCUSSION
The present study reports that dexamethasone, admin-
istered at the induction of anesthesia, prior to surgery for
colorectal cancer was associated with a reduction in the
Elective colorectal cancer resections 
Apr ’08-Feb’16 with anaesthetic 
data
n=556
(no dex=245, dex = 311)
Elective colorectal cancer resection  
Apr’08-Feb’16 propensity score 
matched for preoperative 
dexamethasone
n=276
(no dex n= 138, dex n = 138)
Unmatched
n=124 (all dex)
Propensity score not assigned due 
to missing covariate data
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(no dex = 107, dex = 49)Propensity score assigned
n=400
(no dex =138, dex = 262)
FIG. 1 Patient flowchart for preoperative dexamethasone before
elective surgery for colorectal cancer. dex dexamethasone
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TABLE 2 Association between preoperative dexamethasone and
outcomes in propensity score-matched patients undergoing any sur-
gery for colorectal cancer [n = 276]
Characteristic All
n (%)
Preoperative dexamethasone p value
No
n (%)
Yes
n (%)
n 276 (100) 138 (50) 138 (50) –
Age, years
\65 102 (37) 54 (39) 48 (35) –
65–74 106 (38) 49 (36) 57 (42)
[74 68 (25) 35 (25) 33 (24)
Sex
Male 161 (58) 79 (57) 82 (59) –
Female 115 (42) 59 (43) 56 (41)
BMI, kg/m2
\20 16 (6) 8 (6) 8 (6) –
20–25 97 (35) 54 (39) 43 (31)
26–30 82 (30) 34 (25) 48 (35)
[30 81 (29) 42 (30) 39 (28)
Smoking
Never 130 (47) 64 (46) 66 (48) –
Ex-smoker 113 (41) 52 (38) 61 (44)
Current 33 (12) 11 (8) 11 (8)
ASA score
1 72 (26) 36 (26) 36 (26) –
2 116 (42) 59 (43) 57 (41)
3 80 (29) 37 (27) 43 (32)
4 8 (3) 6 (4) 2 (1)
Preop mGPS
0 224 (82) 107 (78) 117 (85) –
1 26 (9) 15 (11) 11 (8)
2 26 (9) 16 (11) 10 (7)
Tumor site
Colon 170 (62) 86 (62) 84 (61) –
Rectum 10 (38) 52 (38) 54 (39)
TNM stage
0 7 (3) 4 (3) 3 (2) –
I 69 (25) 30 (22) 39 (28)
II 109 (39) 60 (43) 49 (36)
III 91 (33) 44 (32) 47 (34)
Neoadjuvant treatment
Yes 49 (18) 25 (18) 24 (17) –
No 227 (82) 113 (82) 114 (83)
Approach
Open 184 (67) 93 (67) 91 (66) –
Laparoscopic 92 (33) 45 (33) 47 (34)
Surgery[ 4 h
Yes 94 (34) 44 (32) 50 (36) –
No 182 (66) 94 (68) 88 (64)
Intraoperative transfusion
Yes 13 (5) 6 (4) 7 (5) –
TABLE 2 continued
Characteristic All
n (%)
Preoperative dexamethasone p value
No
n (%)
Yes
n (%)
No 263 (95) 132 (96) 131 (95)
Stoma
Yes 90 (33) 43 (31) 47 (34) –
No 186 (67) 95 (69) 91 (66)
Epidural
Yes 132 (48) 66 (48) 66 (48) –
No 144 (52) 72 (52) 72 (52)
POD 3 CRP
Median,
range, mg/L
143 (17–430) 166 (22–382) 126 (17–430) \0.001
POD 3 CRP[ 150 mg/L
Yes 123 (45) 75 (56) 48 (35) 0.001
No 145 (55) 58 (44) 87 (65)
POD 4 CRP
Median,
range, mg/L
121 (13–415) 121 (13–369) 121 (19–415) 0.241
POD 4 CRP[ 150 mg/L
Yes 80 (34) 46 (38) 34 (29) 0.349
No 158 (66) 75 (62) 83 (71)
POD 3 albumin
Median,
range, mg/L
26 (7–35) 25 (15–35) 26 (7–35) 0.058
POD 3 albumin\ 25 g/L
Yes 96 (37) 52 (40) 44 (33) 0.392
No 166 (63) 78 (60) 88 (67)
POD 4 albumin
Median,
range, mg/L
26 (14–35) 25 (14–35) 26 (16–35) 0.768
POD 4 albumin\ 25 g/L
Yes 88 (37) 48 (40) 40 (34) 0.749
No 150 (63) 72 (60) 78 (66)
Any complication
Yes 115 (42) 68 (49) 47 (34) 0.009
No 161 (58) 70 (51) 91 (66)
Infective complications
Yes 78 (28) 45 (33) 33 (24) 0.134
No 198 (72) 93 (67) 105 (76)
Anastomotic leak
Yes 13 (5) 9 (7) 4 (3) 0.227
No 263 (95) 129 (93) 134 (97)
Clavien–Dindo (0–2/3–5)
Yes 26 (9) 17 (12) 9 (7) 0.152
No 250 (91) 121 (88) 129 (93)
30 day mortality
Yes 2 (1) 2 (2) 0 (0) –
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magnitude of the postoperative SIR and fewer postopera-
tive complications.
Currently, corticosteroids are administered in the peri-
operative period to reduce postoperative nausea and
vomiting.14,15 However, when taken together with existing
evidence,16,17,20 the results of the present study also sug-
gest an important role for reducing the complication rate
following surgery for colorectal cancer by attenuating the
postoperative stress response. Indeed, the use of preoper-
ative corticosteroids represents a potentially simple and
cost-effective method of improving surgical outcomes for a
large surgical population. It was of interest that postoper-
ative CRP retained its association with postoperative
complications in those patients who had received preop-
erative dexamethasone. In particular, the CRP threshold of
150 mg/L on POD 3 remained significantly associated with
all and infective complications in this group of patients in
whom the magnitude of the postoperative SIR was lower as
a whole.21 Indeed, the results of the present study suggest
that the measurement of postoperative CRP in this sub-
group remains useful in the clinical setting. For these
reasons, the present study in colorectal cancer is timely.
There remain long-standing concerns that corticos-
teroids may inhibit collagen formation, and therefore
wound healing, in the postoperative period. However,
neither the present study nor previous meta-analyses have
identified a significant negative association with either
wound complications or anastomotic leak14,15 Furthermore,
there have been some concerns that preoperative corticos-
teroids may have a negative impact on oncologic outcome
following surgery for colorectal cancer; however, the evi-
dence for this is limited in both numbers and length of
follow-up.22
The mechanisms by which corticosteroids exert their
anti-inflammatory action remain poorly understood. Inhi-
bition of nuclear factor jB (NF-jB) leads to a
downregulatory effect on lymphoid tissue and thus adap-
tive immune responses.23 In addition, attenuation of the
innate immune response and myeloid tissues occurs as a
consequence of reduction of the transcription of proin-
flammatory cytokines such as IL-6, alongside the inhibition
of cyclooxygenase-dependent pathways by increasing the
transcription of lipocortins.15,24,25
An important implication of the present and previous
results is that postoperative complications are themselves
recognized to have a negative impact on oncologic out-
comes.26 Indeed, the generation of a prometastatic
environment through systemic inflammation, as part of the
surgical injury and the severity of postoperative compli-
cations, has been proposed to promote metastatic disease
progression.27 Furthermore, it has been proposed that this
host response to both the tumor and surgery should become
a target for intervention.28 Indeed, it may be hypothesized
that a reduction in the magnitude of the postoperative SIR,
with a consequent reduction in postoperative complication
rates, may improve long-term outcomes following surgery
for colorectal cancer. Strategies such as the prospective
evaluation of perioperative corticosteroids represent a
logical starting point.
The main limitation of the present study was its retro-
spective nature. Significant imbalance between the two
groups meant that propensity score matching was used to
obtain balanced groups for determination of the treatment
effect; however, this resulted in the exclusion of a signif-
icant proportion of patients, and does not necessarily help
those confounders that are either unmeasured or
unknown.29 Nonetheless, it was reassuring that the overall
treatment effect and its magnitude were similar among the
unmatched cohort, the matched cohort, and when propen-
sity regression was applied.30 In addition, the nature of the
TABLE 2 continued
Characteristic All
n (%)
Preoperative dexamethasone p value
No
n (%)
Yes
n (%)
No 274 (99) 136 (98) 138 (100)
Adjuvant treatment
Yes 65 (28) 31 (25) 34 (31) 0.728
No 168 (72) 92 (75) 76 (69)
BMI body mass index, ASA American Society of Anesthesiologists,
POD postoperative day, CRP C-reactive protein, mGPS preoperative
modified Glasgow Prognostic score, Preop preoperative
TABLE 3 Odds ratios for exceeding the CRP threshold of 150 mg/L on POD 3, and postoperative complications with respect to preoperative
dexamethasone across the propensity score methods
Propensity score model N POD 3 CRP[ 150 mg/L [OR (95% CI)] Complication [OR (95% CI)]
Unadjusted 556 0.40 (0.28–0.57) 0.57 (0.41–0.80)
Regression adjustment 400 0.53 (0.34–0.83) 0.62 (0.40–0.96)
Stratification by quintiles (ATE) 400 0.41 (0.25–0.57) 0.62 (0.29–0.95)
Matched 1:1 276 0.42 (0.26–0.70) 0.53 (0.33–0.86)
POD postoperative day, CRP C-reactive protein, OR odds ratio, CI confidence interval, ATE average treatment effect
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analysis prevented the assessment of any dose–response
relationship.
CONCLUSIONS
The results of the present study suggest that the use of
preoperative corticosteroids is associated with both atten-
uation of the magnitude of the SIR and fewer
complications following surgery for colorectal cancer. This
would suggest that the magnitude of the postoperative SIR
and postoperative complications are causally related.
Optimal doses and treatment regimens are yet to be
determined. Indeed, further prospective randomized trials
are necessary before recommendations regarding the use of
preoperative dexamethasone in the context of the postop-
erative SIR can be made.
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